Stonegate Capital Partners Publishes Research Report on PharmaCyte Biotech
February 10 2016 - 9:32AM
PharmaCyte Biotech, Inc. (OTCQB:PMCB), a clinical stage
biotechnology company focused on developing targeted treatments for
cancer and diabetes using its signature live-cell encapsulation
technology, Cell-in-a-Box®, announced today that Stonegate Capital
Partners (Stonegate), a privately held corporate advisory firm
based in Dallas, Texas, with offices in New York and Boston, issued
a Research Report featuring PharmaCyte Biotech. The report can be
viewed at http://stonegateinc.com/reports/Pharma_Feb_2016.pdf
PharmaCyte Biotech’s Chief Executive Officer,
Kenneth L. Waggoner, commented on the report saying, “In our
opinion the Research Report released by Stonegate Capital Partners
and authored by Senior Research Analyst Laura S. Engel is
comprehensive and captures the essence of what we are trying to
accomplish at PharmaCyte. Particular emphasis is placed on the two
major programs underway that employ our proprietary Cell-in-a-Box®
live-cell encapsulation technology to tackle two of the most
difficult to treat diseases in the world - cancer and
diabetes.”
Stonegate’s Senior Research Analyst, Laura S.
Engel, authored the Research Report, which focuses on PharmaCyte’s
clinical development of a variety of potential therapies across
several areas of disease utilizing its novel live cell
encapsulation platform, Cell-in-a-Box®.
Stonegate’s Senior Research Analyst writes that
PharmaCyte offers a significant opportunity for investors looking
to participate in this development. “We believe that PMCB has a
solid pathway towards commercialization with the approach outlined
for its Phase 2b study for pancreatic cancer patients set to begin
in the Q2-Q3 of calendar year 2016. Additionally, management will
be actively moving other potential treatments along; these
treatments are related to malignant ascites fluid accumulation in
the abdomens of patients with abdominal cancers and Type 1 and Type
2 diabetes. Positive news flow should yield investor returns as the
Company accomplishes its milestones that have been set for
2016.”
Senior Research Analyst Laura S. Engel started a
career in public accounting following graduation from the
University of Virginia, McIntire School of Business, with a B.S. in
Accounting. After several years with Arthur Andersen, Engel
transitioned in industry where she worked for several publicly
traded companies, managing both domestic and international
accounting operations. Engel subsequently transitioned into the
finance realm, joining a Financial Services consulting team with
KPMG Consulting focusing on systems implementations for several
Wall Street banks. She later joined a smaller wealth management
group, servicing a book of clientele through investment management
and financial planning. Since 2003, Engel has teamed with Stonegate
and worked in several areas of the business.
About PharmaCyte Biotech
PharmaCyte Biotech is a clinical stage biotechnology company
focused on developing and preparing to commercialize treatments for
cancer and diabetes based upon a proprietary cellulose-based live
cell encapsulation technology known as “Cell-in-a-Box®.” This
unique and patented technology will be used as a platform upon
which treatments for several types of cancer and diabetes are being
developed. PharmaCyte’s treatment for cancer involves encapsulating
genetically modified live cells that convert an inactive
chemotherapy drug (ifosfamide) into its active or “cancer-killing”
form. These encapsulated live cells are placed as close to a
cancerous tumor as possible. Once implanted in a patient, a
chemotherapy drug which needs to be activated in the body (prodrug)
is then given intravenously at one-third the normal dose. The
ifosfamide is carried by the circulatory system to where the
encapsulated cells have been placed. When ifosfamide, which is
normally activated in the liver, comes in contact with the
encapsulated live cells, activation of the chemotherapy drug takes
place at the source of the cancer without any side effects from the
chemotherapy. This “targeted chemotherapy” has proven remarkably
effective and safe to use in past clinical trials.
In addition to developing a novel treatment for
cancer, PharmaCyte is developing a treatment for Type 1 diabetes
and Type 2 insulin-dependent diabetes. PharmaCyte plans to
encapsulate a human cell line that has been genetically engineered
to produce, store and release insulin in response to the levels of
blood sugar in the human body. The encapsulation will be done using
the Cell-in-a-Box® technology.
Safe Harbor
This press release may contain forward-looking statements
regarding PharmaCyte Biotech and its future events and results that
involve inherent risks and uncertainties. The words "anticipate,"
"believe," "estimate," "expect," "intend," "plan" and similar
expressions, as they relate to PharmaCyte or its management, are
intended to identify forward-looking statements. Important factors,
many of which are beyond the control of PharmaCyte, could cause
actual results to differ materially from those set forth in the
forward-looking statements. They include PharmaCyte's ability to
continue as a going concern, delays or unsuccessful results in
preclinical and clinical trials, flaws or defects regarding its
product candidates, changes in relevant legislation or regulatory
requirements, uncertainty of protection of PharmaCyte’s
intellectual property and PharmaCyte’s continued ability to raise
capital. PharmaCyte does not assume any obligation to update any of
these forward-looking statements.
More information about PharmaCyte Biotech can be
found at www.PharmaCyte.com. It can also be obtained by contacting
Investor Relations.
Investor Relations:
PharmaCyte Biotech, Inc.
Investor Relations Department
Telephone: 917.595.2856
Email: info@PharmaCyte.com